You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Drugs in MeSH Category Leprostatic Agents


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma Pharms RIFAMPIN rifampin INJECTABLE;INJECTION 205039-001 Mar 3, 2016 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis LAMPRENE clofazimine CAPSULE;ORAL 019500-001 Dec 15, 1986 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising DAPSONE dapsone TABLET;ORAL 207165-001 May 8, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising DAPSONE dapsone TABLET;ORAL 207165-002 Jul 20, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol-myers THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.